[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ZA984826B - Novel anti-diabetic composition. - Google Patents

Novel anti-diabetic composition.

Info

Publication number
ZA984826B
ZA984826B ZA9804826A ZA984826A ZA984826B ZA 984826 B ZA984826 B ZA 984826B ZA 9804826 A ZA9804826 A ZA 9804826A ZA 984826 A ZA984826 A ZA 984826A ZA 984826 B ZA984826 B ZA 984826B
Authority
ZA
South Africa
Prior art keywords
novel anti
diabetic composition
diabetic
composition
novel
Prior art date
Application number
ZA9804826A
Other languages
English (en)
Inventor
Jaikrishna Patel
Hamish Ross
Robin Price
Jeffrey Roger Granett
Paul Nigel Wray
Original Assignee
Smithkline Beecham Plc
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9712851.6A external-priority patent/GB9712851D0/en
Application filed by Smithkline Beecham Plc, Smithkline Beecham Corp filed Critical Smithkline Beecham Plc
Publication of ZA984826B publication Critical patent/ZA984826B/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
ZA9804826A 1997-06-05 1998-06-04 Novel anti-diabetic composition. ZA984826B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9711683.4A GB9711683D0 (en) 1997-06-05 1997-06-05 Composition
GBGB9712851.6A GB9712851D0 (en) 1997-06-18 1997-06-18 Composition
PCT/EP1998/003478 WO1998055122A1 (en) 1997-06-05 1998-06-02 Composition comprising 5-[4-[2-(n-methyl-n-2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione

Publications (1)

Publication Number Publication Date
ZA984826B true ZA984826B (en) 1999-08-03

Family

ID=26311662

Family Applications (2)

Application Number Title Priority Date Filing Date
ZA9804826A ZA984826B (en) 1997-06-05 1998-06-04 Novel anti-diabetic composition.
ZA9811572A ZA9811572B (en) 1997-06-05 1998-06-04 Novel anti-diabetic composition.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ZA9811572A ZA9811572B (en) 1997-06-05 1998-06-04 Novel anti-diabetic composition.

Country Status (29)

Country Link
EP (1) EP0998284A1 (es)
JP (1) JP2001521553A (es)
KR (1) KR20010013410A (es)
CN (3) CN1526391A (es)
AP (1) AP1214A (es)
AR (2) AR015120A1 (es)
AU (1) AU8215098A (es)
BG (1) BG104048A (es)
BR (1) BR9810405A (es)
CA (2) CA2292629C (es)
CO (1) CO4940400A1 (es)
DZ (1) DZ2510A1 (es)
EA (1) EA002384B1 (es)
GB (1) GB9711683D0 (es)
HU (1) HUP0004070A3 (es)
ID (1) ID24264A (es)
IL (1) IL133074A0 (es)
MX (1) MXPA99011322A (es)
NO (2) NO995938L (es)
NZ (2) NZ523725A (es)
OA (1) OA11306A (es)
PE (1) PE78899A1 (es)
PL (1) PL337201A1 (es)
SK (1) SK164899A3 (es)
TR (2) TR199902963T2 (es)
TW (1) TW570797B (es)
UY (1) UY25032A1 (es)
WO (1) WO1998055122A1 (es)
ZA (2) ZA984826B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20010040A1 (es) 1999-04-23 2001-03-10 Smithkline Beecham Plc Polimorfo de sal del acido maleico de 5-[4-[2-(n-metil-n-(2-piridil)amino)etoxi]bencil]-tiazolidina-2,4-diona
US20040248945A1 (en) 1999-04-23 2004-12-09 Smithkline Beecham P.L.C. Thiazolidinedione derivative and its use as antidiabetic
ATE246191T1 (de) 1999-04-23 2003-08-15 Smithkline Beecham Plc Polymorph von 5-(4-(2-(n-methyl-n-(2- pyrdyl)amino)äthoxy)benzyl)thiazolidin-2,4-dion maleinsäuresalz
GB0021978D0 (en) 2000-09-07 2000-10-25 Smithkline Beecham Plc Novel pharmaceutical
GB0127805D0 (en) * 2001-11-20 2002-01-09 Smithkline Beecham Plc Pharmaceutical composition
AU2002350965A1 (en) * 2001-12-13 2003-06-23 Smithkline Beecham Plc Toluenesulfonate hydrates of a thiazolidinedione derivative
GB0129876D0 (en) * 2001-12-13 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
GB0129871D0 (en) * 2001-12-13 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
GB0130509D0 (en) * 2001-12-20 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
US7435741B2 (en) 2006-05-09 2008-10-14 Teva Pharmaceutical Industries, Ltd. 2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
DE06252444T8 (de) * 2006-05-09 2009-03-19 Teva Pharmaceutical Industries Ltd. 2-N-{5-[[4-[2-(Methyl-2-pyridinylamino)-ethoxy]-phenyl]-methyl]-2,4-thiazolidindion}-bernsteinsäure, Verfahren zur Herstellung und Zusammensetzungen mit Rosiglitazonmaleat
WO2015008234A1 (en) * 2013-07-17 2015-01-22 Glenmark Pharmaceuticals S.A. Bicyclic heterocyclic compounds as ror gamma modulators

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3856378T2 (de) * 1987-09-04 2000-05-11 Beecham Group P.L.C., Brentford Substituierte Thiazolidindionderivate
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
WO1995021608A1 (en) * 1994-02-10 1995-08-17 Smithkline Beecham Plc Use of insulin sensitisers for treating renal diseases
KR19990036290A (ko) * 1995-08-10 1999-05-25 로즈 암스트롱 비인슐린 의존성 진성 당뇨병 환자에 대한 외인성 인슐린 투여량의 감소 방법
AU7604596A (en) * 1995-11-17 1997-06-11 Warner-Lambert Company A method of treating myotonic dystrophy
NZ314406A (en) * 1996-03-18 2000-12-22 Sankyo Co Treatment or prophylaxis of pancreatitis with a medicament containing an insulin sensitiser including oxazoles and thiazoles
EP0921798A1 (en) * 1996-07-12 1999-06-16 Smithkline Beecham Plc Novel treatment of leptine resistance

Also Published As

Publication number Publication date
JP2001521553A (ja) 2001-11-06
NO995938D0 (no) 1999-12-03
EA199901116A1 (ru) 2000-06-26
PL337201A1 (en) 2000-08-14
AR015120A1 (es) 2001-04-18
BR9810405A (pt) 2000-08-29
AP1214A (en) 2003-10-08
WO1998055122A1 (en) 1998-12-10
CN1430959A (zh) 2003-07-23
CA2292629A1 (en) 1998-12-10
AU8215098A (en) 1998-12-21
IL133074A0 (en) 2001-03-19
ID24264A (id) 2000-07-13
PE78899A1 (es) 1999-10-22
CA2292629C (en) 2004-01-06
KR20010013410A (ko) 2001-02-26
BG104048A (bg) 2000-07-31
NZ513922A (en) 2001-09-28
NZ523725A (en) 2004-09-24
CO4940400A1 (es) 2000-07-24
UY25032A1 (es) 1998-11-26
HUP0004070A2 (hu) 2002-02-28
SK164899A3 (en) 2000-11-07
ZA9811572B (en) 1999-07-22
DZ2510A1 (fr) 2003-01-25
TR199902963T2 (xx) 2000-02-21
TR200002790T2 (tr) 2001-11-21
CN1259050A (zh) 2000-07-05
AP9901696A0 (en) 1999-12-31
EA002384B1 (ru) 2002-04-25
TW570797B (en) 2004-01-11
NO995938L (no) 2000-02-02
CN1526391A (zh) 2004-09-08
CN1112926C (zh) 2003-07-02
HUP0004070A3 (en) 2002-03-28
GB9711683D0 (en) 1997-08-06
AR008198A1 (es) 1999-12-29
MXPA99011322A (es) 2004-12-02
OA11306A (en) 2003-10-22
EP0998284A1 (en) 2000-05-10
CA2333352A1 (en) 1998-12-10
NO20040738L (no) 2000-02-02

Similar Documents

Publication Publication Date Title
ZA984849B (en) Compositions.
ZA983695B (en) Adhesive composition.
GB9704524D0 (en) Composition
GB9715203D0 (en) Composition
GB9713620D0 (en) Composition
ZA9811572B (en) Novel anti-diabetic composition.
ZA9811502B (en) Novel composition.
GB9715489D0 (en) Composition
GB9714010D0 (en) Composition
GB9726777D0 (en) Composition
PL338017A1 (en) Novel composition
EP0958806A4 (en) HAIR COLORING COMPOSITION
ZA200006118B (en) Novel composition.
GB9726284D0 (en) Composition
GB9701031D0 (en) Composition
GB9714359D0 (en) Composition
ZA200000192B (en) Novel composition.
GB9826467D0 (en) Composition
ZA981739B (en) Composition.
GB9724975D0 (en) Composition
GB9705110D0 (en) Composition
EG23068A (en) Pesticidale composition
ZA99556B (en) Cementitious composition.
ZA991829B (en) Novel composition.
GB9718910D0 (en) Composition